Eisai and Biogen said the FDA approved an sBLA for a once-weekly subcutaneous initiation dose of LEQEMBI IQLIK (lecanemab-irmb), expanding the dosing option for the therapy. The approval is a meaningful positive regulatory milestone that could broaden patient convenience and uptake. Overall, the news should be modestly supportive for expectations around LEQEMBI’s adoption.
Eisai and Biogen said the FDA approved an sBLA for a once-weekly subcutaneous initiation dose of LEQEMBI IQLIK (lecanemab-irmb), expanding the dosing option for the therapy. The approval is a meaningful positive regulatory milestone that could broaden patient convenience and uptake. Overall, the news should be modestly supportive for expectations around LEQEMBI’s adoption.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialOverall Sentiment
moderately positive
Sentiment Score
0.45
Ticker Sentiment
